Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ultragenyx Pharmaceutical Inc. - Common Stock
(NQ:
RARE
)
42.49
-1.03 (-2.37%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ultragenyx Pharmaceutical Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
A Preview Of Ultragenyx Pharmaceutical's Earnings
May 03, 2023
Via
Benzinga
Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate Update
April 27, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Expert Ratings for Ultragenyx Pharmaceutical
April 26, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 26, 2023
April 26, 2023
Via
Benzinga
Where Ultragenyx Pharmaceutical Stands With Analysts
February 17, 2023
Via
Benzinga
Earnings Scheduled For February 16, 2023
February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...
Via
Benzinga
Earnings Preview: Ultragenyx Pharmaceutical
February 15, 2023
Via
Benzinga
Analyst Expectations for Ultragenyx Pharmaceutical's Future
January 18, 2023
Via
Benzinga
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 19, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
March 29, 2023
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine.
Via
InvestorPlace
Ultragenyx to Present at Guggenheim’s Genomic Medicines and Rare Disease Days
March 28, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 21, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
The Latest Analyst Ratings for Ultragenyx Pharmaceutical
December 30, 2022
Via
Benzinga
Analyst Expectations for Ultragenyx Pharmaceutical's Future
December 30, 2022
Via
Benzinga
Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
March 14, 2023
Dr. Camille Bedrosian to continue employment as strategic development advisor with the company
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference
February 28, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
February 16, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Where Ultragenyx Pharmaceutical Stands With Analysts
November 03, 2022
Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter:
Via
Benzinga
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update
February 09, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones
January 06, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
What You Missed On Wall Street On Friday
December 31, 2022
In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold.
Via
Talk Markets
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 21, 2022
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Present at Piper Sandler Healthcare Conference
November 22, 2022
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 18, 2022
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Departure of Chief Financial Officer
November 10, 2022
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Present at Upcoming Healthcare Conferences
November 09, 2022
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
November 09, 2022
On Wednesday, 283 companies set new 52-week lows.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022
November 03, 2022
Upgrades
Via
Benzinga
Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
November 02, 2022
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
